Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
5.50
-0.18 (-3.17%)
At close: Apr 24, 2025, 4:00 PM
5.49
-0.01 (-0.18%)
Pre-market: Apr 25, 2025, 4:00 AM EDT
Precision BioSciences Employees
Precision BioSciences had 108 employees as of December 31, 2024. The number of employees decreased by 1 or -0.92% compared to the previous year.
Employees
108
Change (1Y)
-1
Growth (1Y)
-0.92%
Revenue / Employee
$636,074
Profits / Employee
$66,361
Market Cap
58.17M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
DTIL News
- 9 days ago - Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - Business Wire
- 23 days ago - Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - Business Wire
- 4 weeks ago - Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - Business Wire
- 4 weeks ago - Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - Business Wire
- 5 weeks ago - Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 - Business Wire
- 5 weeks ago - Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Business Wire
- 5 weeks ago - Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B - Business Wire
- 6 weeks ago - iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting - Business Wire